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OBJECTIVES This was a retrospective analysis to determine the effect of diabetes on outcome in patients
with advanced heart failure (HF), and to determine the effect of beta-blockade in patients
with HF with and without diabetes mellitus.
BACKGROUND In chronic HF the impact on clinical outcomes and therapeutic response of the prevalent
comorbid condition diabetes mellitus has not been extensively investigated.
METHODS We assessed the impact of diabetes on prognosis and effectiveness of beta-blocker therapy
with bucindolol in patients with HF enrolled in the Beta-Blocker Evaluation of Survival Trial
(BEST). We conducted a retrospective analysis to examine the prognosis of patients with
advanced HF with and without diabetes, and the effect of beta-blocker therapy on mortality
and HF progression or myocardial infarction (MI). The database was the 2,708 patients with
advanced HF (36% with diabetes and 64% without diabetes) who were randomized to the
beta-blocker bucindolol or placebo in BEST and followed for mortality, hospitalization, and
MI for an average of two years.
RESULTS Patients with diabetes had more severe chronic HF and more coronary risk factors than
patients without diabetes. Diabetes was independently associated with increased mortality in
patients with ischemic cardiomyopathy (adjusted hazard ratio 1.33, 95% confidence interval
1.12 to 1.58, p  0.001), but not in those with a nonischemic etiology (adjusted hazard ratio
0.98, 95% confidence interval 0.74 to 1.30, p  0.89). Compared with patients without
diabetes, in diabetic patients beta-blocker therapy was at least as effective in reducing death
or HF hospitalizations, total hospitalizations, HF hospitalizations, and MI. Ventricular
function and physiologic responses to beta-blockade were similar in patients with and without
diabetes.
CONCLUSIONS Diabetes worsens prognosis in patients with advanced HF, but this worsening appears to be
limited to patients with ischemic cardiomyopathy. In advanced HF beta-blockade is effective
in reducing major clinical end points in patients with and without diabetes. (J Am Coll
Cardiol 2003;42:914–22) © 2003 by the American College of Cardiology Foundation
Diabetes mellitus is associated with increases in most
adverse cardiovascular events including myocardial infarc-
tion (MI), chronic heart failure (HF) and stroke (1,2).
Diabetes is also associated with structural and metabolic
abnormalities that can adversely affect myocardial function
(3–10). However, the impact of diabetes on the natural
history of HF has not been extensively investigated. A single
previous study (11) has reported a worsened prognosis in
mild-moderate HF populations with diabetes, and those
data suggested the effect is limited to patients with ischemic
as compared with nonischemic cardiomyopathy. Moreover,
the impact of diabetes has not been examined in subjects
with more advanced HF who are also on contemporary HF
therapy such as angiotensin-converting enzyme inhibitors
and beta-blockers.
A number of compensatory mechanisms are activated in
response to HF that serve the purpose of initially stabilizing
cardiac performance, but which eventually contribute to
progressive left ventricular dysfunction and remodeling (12).
Inhibition of this so-called neurohormonal response is now
a well-accepted treatment paradigm, and beta-blockers are
an established component of this therapeutic approach.
However, the adverse effects of the diabetic process or
unwanted metabolic effects of anti-adrenergic therapy could
add a pathophysiologic burden that might be sufficient to
abrogate the clinical benefits of beta-blocker treatment in
HF patients with diabetes.
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The Beta-Blocker Evaluation of Survival Trial (BEST)
investigated beta-blockade with bucindolol for treatment of
patients with advanced HF, and the primary outcomes have
been reported previously (13). In clinical practice beta-
blockers have been used with reluctance in diabetic subjects
because of the fear of adverse effects including effects on
insulin resistance and, in particular, fear of hypoglycemia in
subjects receiving insulin. We analyzed the BEST database
to investigate the prognosis of patients with advanced HF
with and without diabetes, and to assess the effect of
beta-blocker therapy.
METHODS
Study objectives. This was a retrospective analysis to
determine the effect of diabetes on outcome in patients with
advanced HF, and to examine the effect of beta-blockade in
HF patients with and without diabetes mellitus.
Study design. The main BEST results have been described
previously (13). The trial was stopped prematurely on the
recommendation of the Data and Safety Monitoring Board
on the basis of the “totality of evidence derived from BEST
and other studies” (13). Specifically, the data in BEST
subpopulations (class III, non-African-American patients)
that had been investigated in other large and recently
reported survival trials (14,15) were consistent with a
beta-blocker-related reduction in mortality (13,16), and
this, coupled with concern about loss of equipoise in an
increasing number of BEST trial investigators (13)
prompted the stopping recommendation.
All patients had a left ventricular ejection fraction
(LVEF) 0.35, and were in New York Heart Association
(NYHA) functional class III or IV. Patients were required
to be on optimal medical therapy including, if tolerated, an
angiotensin-converting enzyme inhibitor for at least one
month. Randomization to bucindolol or to a matched
placebo was stratified at each clinical site by: 1) etiology of
HF (ischemic or nonischemic cardiomyopathy), 2) LVEF
0.20 or0.20, 3) gender, and 4) race (black vs. nonblack).
Ischemic cardiomyopathy HF etiology was defined as sig-
nificant (70% narrowing in a major epicardial vessel)
coronary artery disease by angiography or evidence of
previous MI. In BEST 2,708 patients were enrolled, with a
mean follow-up of two years (13).
Patients were considered to have diabetes if they had a
documented history of diabetes mellitus at baseline. Data
were gathered on Diabetes History Case Report Forms for
childhood (18 years) versus adult onset of diabetes, type of
treatment received (insulin, oral hypoglycemic, or dietary
only), and whether the patient had documented end-organ
disease (retinopathy, neuropathy, or nephropathy). Hypo-
glycemia, hyperglycemia, or weight gain as adverse events
was determined from protocol-defined Adverse Medical
Events Forms.
Treatment and follow-up. Patients were initiated on study
medication at 3 mg twice daily, and then uptitrated on
bucindolol or placebo weekly as tolerated, to a maximum
dose of 50 mg twice daily for patients weighing 75 kg and
100 mg twice daily for patients weighing 75 kg (13).
Patients were examined at three, six, and 12 months
following randomization and at six-month intervals there-
after. Electrocardiogram, chest X-ray, ventricular function,
plasma norepinephrine, and laboratory measurements were
evaluated at baseline and repeated three and 12 months after
randomization (13). Ventricular function was assessed by
radionuclide ventriculography (13).
End points. The primary end point of BEST was all-cause
mortality. Secondary end points included 1) cardiovascular
mortality (defined as mortality due to pump failure, sudden
death, and ischemic events), 2) total hospitalizations,
3) hospitalizations due to HF, 4) the combination of death
or heart transplantation, 5) LVEF at three and 12 months,
and 6) MI (13). For the current analysis, the additional
combined end point of death (from any cause) or HF
hospitalization was examined. An end points committee
blinded to the treatment assignment centrally adjudicated
cause of death and MI.
Statistical methods. Continuous data are reported as
means and standard deviations or medians, with intergroup
comparisons performed by t or Wilcoxon rank-sum tests
unless otherwise noted. Categorical data are reported as
proportions, with intergroup comparisons by the chi-square
or Fisher’s exact test. Cumulative time to event curves
including the combined end point of death or HF hospi-
talization were constructed using Kaplan-Meier methods,
and differences between groups were evaluated using the
log-rank test. Cox proportional hazards regression was used
to examine the effects of diabetes, etiology of HF, and
treatment with bucindolol in the presence of prespecified
covariates. All analyses were conducted using the intention-
to-treat principle. A p value of 0.05 was used to indicate
statistical significance.
RESULTS
Baseline clinical characteristics. Table 1 summarizes clin-
ical characteristics by diabetic status. Generally, patients
with diabetes had more adverse prognostic indicators than
patients without diabetes reflected by a slightly older age,
more class IV patients, more ischemic cardiomyopathy
etiology, more Blacks, more vascular disease, a higher
baseline heart rate, and a higher creatinine level. However,
a few baseline parameters were more favorable in patients
Abbreviations and Acronyms
BEST  Beta-Blocker Evaluation of Survival Trial
HF  heart failure
HR  hazard ratio
LVEF  left ventricular ejection fraction
MI  myocardial infarction
NYHA  New York Heart Association
RVEF  right ventricular ejection fraction
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with diabetes, including a higher body mass index, lower
incidence of smokers, a higher systolic blood pressure, and a
lower plasma norepinephrine.
Prognostic impact of diabetes. We examined the effect of
diabetes mellitus on outcomes in a multivariate analysis
(Table 2). The final model included NYHA functional
class, LVEF, systolic blood pressure, etiology of HF, age,
race, gender, body mass index, cholesterol, creatinine, treat-
ment group assignment (bucindolol and placebo), and
whether taking diuretics or vasodilators at baseline. After
adjusting for other known risk factors, diabetes was associ-
ated with an increased risk of death, cardiovascular death,
pump failure death, and HF hospitalization. Additionally,
in patients with diabetes insulin therapy was a significant
predictor of cardiovascular mortality both in univariable
(hazard ratio [HR] 1.35, 95% confidence interval [CI] 1.08
to 1.70) and multivariable (HR 1.30, 95% CI 1.03 to 1.65)
analyses.
Effect of ischemic cardiomyopathy HF etiology on sur-
vival. In patients with an ischemic cardiomyopathy etiol-
ogy of HF, diabetes conferred an increased risk for a number
of adverse cardiovascular events including all-cause death,
cardiovascular death, pump failure death and the combined
end point of death or HF hospitalization (Table 3). There
Table 1. Baseline Patient Clinical Characteristics by Diabetic Status
Characteristic
Diabetes
(n  964)
No Diabetes
(n  1,744) p Value
Demographics
Age (yrs) mean (range) 61  10.4 (23–88) 60  13.3 (19–93)  0.0001
Men 750 (78%) 1,365 (78%) 0.78
Body mass index (kg/m2) 29  6.1 27  5.9  0.0001
Median CHF duration (months) 39.5 36 0.002
Current smoker 136 (14%) 338 (19%) 0.001
NYHA class III 865 (90%) 1,617 (93%) 0.007
Ischemic etiology 645 (67%) 942 (54%)  0.0001
Black not Hispanic 244 (25%) 383 (22%) 0.048
Cardiovascular history
Hypertension 672 (70%) 924 (53%)  0.0001
Hyperlipidemia 498 (52%) 672 (39%)  0.0001
History of MI 460 (48%) 684 (39%)  0.0001
Peripheral vascular disease 237 (25%) 204 (12%)  0.0001
Coronary bypass surgery 309 (32%) 473 (27%) 0.007
Coronary angioplasty/PTCA/DCA 170 (18%) 253 (15%) 0.032
Hemodynamics/ventricular function
Heart rate (beats/min) 83  12.7 81  13.4  0.0001
Blood pressure (mm Hg)
Systolic 120  19.0 116  17.3  0.0001
Diastolic 72  11.1 71  11.3 0.06
LVEF ( 100) 23.4  7.0 22.8  7.4 0.023
RVEF ( 100) 34.4  13.5 35.1  13.5 0.26
Atrial fibrillation 82 (9%) 221 (13%) 0.001
Creatinine (mg/dl) 1.3  0.4 1.2  0.4  0.0001
Neurohormonal status
Plasma norepinephrine (pg/ml)
Median 401 453  0.0001
Mean 476  329 537  351
CHF  congestive heart failure; DCA  directional coronary atherectomy; LVEF  left ventricular ejection fraction; MI 
myocardial infarction; PTCA  percutaneous transluminal coronary angioplasty; NYHA  New York Heart Association;
RVEF  right ventricular ejection fraction.
Table 2. Prognostic Impact of Diabetes Mellitus for Primary and Secondary Outcomes Adjusted
for Risk Factors (Overall and by Ischemic Versus Nonischemic Etiology of Cardiomyopathy)
End Point
Diabetes
(n  964)
No Diabetes
(n  1,744) HR* (95% CI) p Value # Events
All-cause death 347 (36%) 513 (29%) 1.22 (1.06–1.41) 0.007 845
CV death 301 (31%) 430 (25%) 1.26 (1.08–1.47) 0.004 720
Pump failure death 117 (12%) 145 (8%) 1.50 (1.15–1.94) 0.002 258
Sudden death 153 (16%) 232 (13%) 1.16 (0.93–1.43) 0.19 380
HF hospitalization 405 (42%) 640 (37%) 1.16 (1.02–1.32) 0.027 1,026
HF hospitalization  death 559 (58%) 862 (49%) 1.19 (1.06–1.33) 0.003 1,398
Hazard ratios (HR) compare diabetics to nondiabetics. *Hazard ratios and 95% confidence intervals (CI) adjusted for baseline
creatinine, left ventricular ejection fraction, New York Heart Association functional class, systolic blood pressure, age, etiology
of heart failure, cholesterol, body mass index, diuretics, gender, vasodilators, race, and randomization to bucindolol or placebo.
CV  cardiovascular; HF  heart failure.
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were also nonsignificant trends towards a diabetes-conferred
increased risk of sudden death and HF hospitalization in
this subgroup. In contrast, in patients with nonischemic
etiology, diabetes was not a predictor for all-cause death,
cardiovascular death, or sudden death. However, there were
strong nonsignificant trends for an increase in risk for pump
failure death, HF hospitalization, and death or HF hospi-
talization in patients with versus those without diabetes in
the nonischemic group.
Figure 1 shows the survival of patients according to HF
etiology and diabetes status. In patients with a non-ischemic
etiology, survival is comparable in patients with vs. those
without diabetes (log rank p value 0.85, 12-month respec-
tive rates of 88.8% and 88.4%), and better than in ischemic
cardiomyopathy (respective 12-month rates of 77.4% and
83.2% in patients with and without diabetes). Therefore,
ischemic cardiomyopathy patients with diabetes had the
greatest risk for mortality, which at 12 months was respec-
tively 34% or 101% higher than in patients with nondiabetic
ischemic or diabetic nonischemic cardiomyopathy.
Effect of beta-blocker therapy in diabetics. Baseline char-
acteristics by treatment group in patients with diabetes were
comparable to those without diabetes (data not shown).
Treatment outcomes by diabetes status are given in Table 4
Table 3. Effect of Diabetes vs. No Diabetes on Clinical End Points in Ischemic or Nonischemic
Cardiomyopathy
End Point
Ischemic Etiology (n  1,562) Nonischemic Etiology (n  1,099)
HR† (95% CI) p Value HR* (95% CI) p Value
All-cause death 1.33 (1.12–1.58) 0.001 0.98 (0.74–1.30) 0.89
CV death 1.36 (1.14–1.64) 0.0009 1.01 (0.74–1.38) 0.95
Pump failure death 1.44 (1.06–1.94) 0.019 1.64 (0.99–2.74) 0.056
Sudden death 1.28 (0.99–1.64) 0.058 0.90 (0.59–1.38) 0.64
HF hospitalization 1.14 (0.97–1.34) 0.113 1.23 (0.98–1.54) 0.074
HF hospitalization  death 1.19 (1.04–1.37) 0.011 1.18 (0.97–1.44) 0.10
*Hazard ratios (HR) for patients with diabetes vs. non-diabetic patients and 95% confidence intervals (CI) adjusted for baseline
creatinine, left ventricular ejection fraction, New York Heart Association functional class, systolic blood pressure, age,
cholesterol, body mass index, diuretics, gender, vasodilators, race, and randomization to bucindolol or placebo.
HF  heart failure; CV  cardiovascular.
Figure 1. Survival of patients according to diabetic and coronary artery disease status in the entire cohort (placebo or bucindolol treatment). Hazard ratio
(HR) and 95% confidence interval compare diabetics to nondiabetics. Estimates are adjusted for treatment group assignment. CAD  coronary artery
disease (ischemic cardiomyopathy); DM  diabetes mellitus.
917JACC Vol. 42, No. 5, 2003 Domanski et al.
September 3, 2003:914–22 HF in Diabetics
and Figure 2. As shown in Table 4, in patients with diabetes
treatment with bucindolol was associated with a reduction
in total hospitalizations, HF hospitalizations, and the com-
bined end point of death or HF hospitalization. In patients
without diabetes bucindolol therapy was associated with a
reduction in the end points of death or cardiac transplan-
tation, HF hospitalizations, and death or HF hospitaliza-
tion. These end points plus cardiovascular deaths, MI, and
death or MI were reduced by bucindolol in the entire
cohort. Although the occurrence of MI was low in the
BEST patients, the incidence was reduced by 48% in
diabetics and by 42% in nondiabetics. In the entire cohort
the reduction in MI was by 43% (hazard ratio 0.57 [0.34.
0.94], p  0.024), and 57 of the 65 total MIs were in
ischemic cardiomyopathy patients.
Figure 2 gives the substantial (at 12 months of follow-up
a reduction in relative risk by 20.8%, 24.5%, and 20.0% in
the total cohort, in diabetic patients, and in patients without
diabetes, respectively) reduction in the combined end point
of death or HF hospitalization associated with bucindolol
therapy.
As shown in Table 5, a number of parameters that have
prognostic importance were improved with bucindolol ther-
apy. In both patients with and without diabetes, at three and
12 months of follow-up increases in both left and right
ventricular ejection fractions (RVEF) were higher in
bucindolol- compared with placebo-treated patients. In
patients treated with bucindolol the improvement in LVEF
was similar in patients with and without diabetes. At 12
months the bucindolol-associated increase in RVEF in
patients without diabetes was slightly greater than the
change in diabetic patients, which was only a trend com-
Table 4. Primary and Secondary End Points by Diabetic Status and Treatment Group*
End Point
Diabetes
95% CI p Value†
Placebo
(n  465)
Bucindolol
(n  499) HR*
Primary end point
Death§ 172 (37%) 175 (35%) 0.91 0.74–1.13 0.40
Secondary end points
Cardiovascular death‡ 153 (33%) 148 (30%) 0.87 0.70–1.09 0.23
Sudden death 76 (16%) 77 (15%) 0.91 0.67–1.25 0.57
Pump failure death 63 (14%) 54 (11%) 0.77 0.54–1.11 0.16
Myocardial infarction death 4 (1%) 7 (1%) 1.57 0.46–5.37 0.47
Other 10 (2%) 10 (2%) 0.90 0.37–2.16 0.81
Noncardiovascular death 13 (3%) 20 (4%) 1.36 0.68–2.74 0.39
Heart transplantation 6 (1%) 5 (1%) 0.76 0.23–2.50 0.65
Death or transplantation‡ 175 (38%) 177 (35%) 0.91 0.74–1.12 0.39
Hospitalization (all-cause) 326 (70%) 330 (66%) 0.85 0.73–0.99 0.039
HF hospitalization† 216 (46%) 189 (38%) 0.72 0.60–0.88 0.001
Death or HF hospitalization† 288 (62%) 271 (54%) 0.77 0.65–0.91 0.002
Myocardial infarction‡ 20 (4%) 12 (2%) 0.52 0.26–1.07 0.069
Death or myocardial infarction‡ 181 (39%) 180 (36%) 0.87 0.71–1.08 0.20
End Point
No Diabetes
95% CI p Value†
Placebo
(n  889)
Bucindolol
(n  855) HR*
Primary end point
Death§ 277 (31%) 236 (28%) 0.87 0.73–1.03 0.1134
Secondary end points
Cardiovascular death‡ 236 (27%) 194 (23%) 0.84 0.69–1.02 0.0698
Sudden death 127 (14%) 105 (12%) 0.85 0.66–1.10 0.2096
Pump failure 77 (9%) 68 (8%) 0.90 0.65–1.24 0.5097
Death
Myocardial infarction death 9 (1%) 3 (0%) 0.34 0.09–1.27 0.0924
Other 23 (3%) 18 (2%) 0.79 0.43–1.47 0.4612
Noncardiovascular death 29 (3%) 31 (4%) 1.09 0.66–1.81 0.7416
Heart transplantation 35 (4%) 24 (3%) 0.69 0.41–1.16 0.1569
Death or transplantation§ 305 (34%) 254 (30%) 0.84 0.71–0.99 0.0388
Hospitalization (all-cause) 549 (62%) 499 (58%) 0.95 0.84–1.08 0.4270
HF hospitalization† 353 (40%) 287 (34%) 0.81 0.69–0.95 0.0078
Death or HF hospitalization† 473 (53%) 389 (45%) 0.82 0.71–0.93 0.0030
Myocardial infarction‡ 21 (2%) 12 (1%) 0.58 0.29–1.18 0.1306
Death or myocardial infarction‡ 283 (32%) 239 (28%) 0.86 0.72–1.02 0.0806
*Hazard ratios (HR) compare bucindolol to placebo-treated patients. †p 0.001 bucindolol vs. placebo, entire cohort; ‡p 0.05
bucindolol vs. placebo, entire cohort; §p  0.10 bucindolol vs. placebo, entire cohort. P values reported are unadjusted. Overall
values reported compare the overall treatment group comparisons (bucindolol vs. placebo).
CI  confidence interval, HF  heart failure.
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Figure 2. Effect of bucindolol or placebo treatment on the combined end point of death or heart failure hospitalization, in the entire cohort (A), diabetics
(B), and nondiabetics (C).
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pared to the placebo change. Reduction in heart rate was
much greater at 3 and 12 months in bucindolol-treated
patients, and the degrees of reduction were similar in
patients with and without diabetes. Plasma norepinephrine
levels decreased in bucindolol-treated patients at three
months, to a similar degree in patients with and without
diabetes. At 12 months the reduction in norepinephrine was
significant in patients without diabetes, and only a nonsig-
nificant trend in patients with diabetes in the bucindolol
groups.
In terms of reported adverse events, irrespective of treat-
ment assignment, patients with diabetes versus those with-
out diabetes had significantly more weight gain (38% vs.
30%), hyperglycemia (36% vs. 5%), hypoglycemia (14% vs.
1%), elevated creatinine levels (12% vs. 8%), syncope (12%
vs. 9%), kidney failure (9% vs. 5%), MI (7% vs. 3%), and
cerebrovascular accident (4% vs. 3%). However, treatment
with bucindolol was generally not associated with more
adverse events in either patients with diabetes or those
without. The exceptions were: bradycardia, which in pa-
tients with diabetes or no diabetes respectively was reported
in 11% and 12% of bucindolol-treated compared to 5% (p
0.001 and 5% (p  0.001) in placebo-treated patients; and
presyncope, which was reported at an increased incidence
with bucindolol treatment only in patients with diabetes
(7% of bucindolol-treated patients vs. 4% of placebo pa-
tients, p  0.024). Myocardial infarction reported as an
adverse event (as opposed to adjudicated MI given in
Table 4) was reduced in bucindolol- versus placebo-treated
diabetic (from respective incidences of 10% to 5%, p 
0.005) and nondiabetic (from respective incidences of 5% to
2%, p  0.02) patients.
Importantly, neither hyperglycemia nor hypoglycemia
was reported at a significantly higher frequency in
bucindolol- versus placebo-treated patients with diabetes.
However, among diabetic subjects on insulin therapy,
bucindolol was associated with an increase in hypoglycemia
(28% bucindolol vs. 18% placebo, p  0.017); there was no
difference in hypoglycemia among subjects with diabetes
who were not on insulin therapy (7% bucindolol vs. 8%
placebo, p  NS).
DISCUSSION
Diabetes is a common condition with increasing prevalence
in the U.S. The diabetes prevalence in BEST of 36%
compares to 20% to 37% reported in other HF clinical trials
(17–22), and the large number of patients with diabetes in
BEST allowed us to compare outcomes in them to those in
BEST patients without diabetes. The main findings of this
study are that in an advanced HF population, 1) the
prognostic effect of diabetes on mortality is confined to
those with an ischemic cardiomyopathy etiology, and 2) the
clinical and physiologic benefits of beta-blockade are similar
in patients with and without diabetes. In addition, for the
first time in a chronic HF clinical trial a beta-blocker was
shown to reduce the incidence of MI, a finding that has
implications for many diabetic patients with HF.
Beta-blockade was administered to patients with ad-
vanced HF (NYHA class III and IV) in the form of the
third generation compound bucindolol, which blocks beta1
and beta2-adrenergic receptors, has mild vasodilator prop-
erties that contribute to its good tolerability, has potent
sympatholytic properties that were confirmed in the BEST
trial (13), and on the basis of in vivo (23) and in vitro
(24–26) data has no intrinsic sympathomimetic activity in
functioning human ventricular myocardium. In BEST
bucindolol produced a reduction in mortality in patients
(class III, non–African-American) (13) that heretofore were
the predominant subpopulations investigated in other beta-
blocker mortality trials, and in this population bucindolol’s
efficacy was similar (16) to that of metoprolol CR/XL in the
Metoprolol CR/XL Randomized Intervention Trial in
Congestive Heart Failure (MERIT-HF) (14) and bisopro-
lol in the Cardiac Insufficiency Bisoprolol Study II
(CIBIS-II) (15).
On multivariable analysis, diabetes was strongly and
independently associated with increased mortality. In the
entire cohort diabetes was a predictor of cardiovascular
death, and specifically pump failure, but not sudden death.
Consistent with an adverse effect of diabetes on pump
function, HF hospitalizations were increased in diabetic
patients compared to those without diabetes. Mechanisms
by which diabetes might contribute to progression of LV
Table 5. Treatment Effects on Nonclinical End Points in Diabetics and Nondiabetics ( SD)
Parameter
Diabetes, Treatment Group No Diabetes, Treatment Group
Placebo
(n  465)
Bucindolol
(n  499)
Placebo
(n  889)
Bucindolol
(n  855)
 LVEF 3 months (EF  100)* 2.2  6.9 5.7  8.3† 2.0  6.9 5.4  7.5†
 LVEF 12 months (EF  100)* 3.2  8.3 6.7  10.0† 3.3  8.9 7.6  10.0†
 RVEF 3 months (EF  100)* 1.9  10.9 4.1  10.2‡ 1.2  11.3 4.4  11.9†
 RVEF 12 months (EF  100)* 3.1  12.6 5.1  12.4§ 1.9  12.6 6.3  12.9†
 Heart rate 3 months (beats/min) 1.2  12.2 10.0  12.4† 1.3  13.3 9.0  13.4†
 Heart rate 12 months (beats/min) 1.5  13.8 9.0  13.9† 2.4  13.3 8.3  13.8†
 Norepinephrine 3 months (pg/ml) 15.0  287 79.1  346 33.6  307 67.8  344†
 Norepinephrine 12 months (pg/ml) 36.6  310 9.9  295 49.0  309 29.2  303†
*  change from baseline. †p  0.001 bucindolol vs. placebo, entire cohort; ‡p  0.05 bucindolol vs. placebo, entire cohort; §p  0.10 bucindolol vs. placebo, entire cohort.
EF  ejection fraction; other abbreviations as in Table 1.
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dysfunction are well described (27,28), and an attractive
hypothesis for the adverse effect of diabetes on mortality is
that diabetes confers an additional myopathic risk in sub-
jects with established secondary dilated cardiomyopathies.
However, this additional risk appears to be confined to
ischemic cardiomyopathy, inasmuch as diabetes did not
confer additional mortality risk in patients with nonisch-
emic cardiomyopathy. In BEST the use of insulin was
associated with increased cardiovascular mortality that may
have been a direct consequence of insulin therapy or, more
likely, insulin use was a marker of more severe cardiovascu-
lar effects of diabetes.
In contrast to the lack of an effect on sudden death by
diabetes in the entire cohort, there was a nearly significant
trend for an increase in diabetes-conferred sudden death risk
in the ischemic cardiomyopathy subgroup, with a hazard
ratio of 1.28 (0.99 to 1.64) compared to a hazard ratio of
1.0 in patients with nonischemic cardiomyopathy with
diabetes. These data contributed to the overall increase in
all-cause (by 33%) and cardiovascular mortality (by 36%)
risks conferred by the presence of diabetes in patients with
ischemic cardiomyopathy, compared to patients with non-
ischemic cardiomyopathy who were not at increased risk for
total or cardiovascular death in patients with versus those
without diabetes. A potential explanation for the differential
effect of diabetes on mortality risk in ischemic versus
nonischemic cardiomyopathy patients is the well-known
accumulation of risk factors for coronary artery disease (29),
which may have increased the risk of ischemia-related
sudden death in patients with ischemic cardiomyopathy.
That the etiology of HF appears to be an important
determinant of prognosis in patients with HF and diabetes
agrees with previous observations in the SOLVD patient
population (11), which had less advanced HF than patients
enrolled in BEST. Therefore, our results confirm and
extend those from SOLVD, and the reinforcing findings of
these two studies highlight the need to consider a more
aggressive treatment approach in diabetic patients with
ischemic cardiomyopathy.
The effect of diabetes on myopathic mechanisms or
myocardial ischemia could influence the response of HF
patients to beta-blockade. However, our data do not suggest
a differential response to beta-blockers in diabetics versus
nondiabetics. Diabetes did not influence the effect of beta-
blockade on adrenergically related parameters thought to
contribute to the therapeutic response to beta-blockade,
including heart rate, LVEF or RVEF, and plasma norepi-
nephrine. Importantly, there was no differential sympatho-
lytic effect of bucindolol in diabetic versus nondiabetic
patients; such effects likely contributed to less desirable
treatment effects in the Class IV and black subpopulations
of BEST (30). Another way in which the presence of
diabetes could influence the response to beta-blockade
would be to enhance the anti-ischemic properties of beta-
blockers. Indeed, in this study we demonstrate for the first
time in a beta-blocker trial in chronic HF a reduction in MI.
In BEST MI was an adjudicated secondary end point, and
it was reduced in bucindolol-treated patients by40% (p
0.05) in the entire BEST Cohort. However, the overall
prevalence of clinically evident MI was low in BEST
(4% and 2% in placebo-treated diabetic and nondiabetic
patients, respectively), and this small absolute differential
prevalence was not high enough to have influenced the
treatment effect of bucindolol in patients with versus those
without diabetes. Therefore, in BEST, beta-adrenergic
blockade as a treatment for advanced chronic HF was
equally effective in patients with and without diabetes.
The combined end point of death or HF hospitalizations
is probably the most sensitive major indicator of clinical
efficacy of HF treatment, because it combines two high
prevalence end points that may be directly influenced by
therapy that favorably alters HF natural history. Our data
demonstrate that bucindolol was effective in reducing the
prevalence of this combined end point, with highly statis-
tically significant reductions by 21% in the entire cohort,
24% in diabetic patients, and 20% in non-diabetics. These
data support the ideas that in an advanced HF population
bucindolol therapy is overall efficacious, and there is no
difference in beta-blocker response between patients with
and those without diabetes. Regarding the latter point, the
data suggest that HF patients with diabetes derive benefit
from beta-blockade despite the additional cardiovascular
disease burden conferred by this pervasive disorder. A
similar conclusion has been reached with the third-
generation beta-blocker carvedilol in another HF clinical
trial database, albeit with a smaller sample size and a more
limited analysis (31). However, until more data are available
with other beta-blockers it would be prudent to consider the
effects reported in this study as drug-specific rather than a
class effect.
Hypoglycemia is more frequent in patients with diabetes
who are receiving insulin treatment, and in BEST Trial
patients with diabetes bucindolol treatment was associated
with increased hypoglycemia only in patients who were
receiving insulin therapy. Hyperglycemia was not increased
in patients with diabetes treated with bucindolol. These
data suggest that beta-blockade with bucindolol does not
worsen insulin sensitivity, and in fact may have increased it.
In this regard, in the setting of hypertension other vasodi-
lating beta-blockers also have not worsened insulin sensi-
tivity, in contrast to beta1-receptor selective blockers (32).
Bucindolol was also associated with a slight increase in
presyncope in diabetic patients, probably due to an aggra-
vation in autonomic dysfunction known to accompany
diabetes. However, overall bucindolol appeared to have a
very acceptable safety profile in patients with advanced HF
and diabetes.
In conclusion, diabetes worsens prognosis in patients
with HF, but this worsening appears to be limited to
patients with an ischemic cardiomyopathy etiology. The
third-generation beta-blocker bucindolol was equally effec-
tive in reducing the combined end point of death or HF
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hospitalization and other clinical end points in patients
with, compared to those without diabetes. Finally, in BEST
beta-blockade with bucindolol lowered the incidence of MI,
and this beneficial property might be important in HF
patient populations exhibiting a greater degree of active
ischemia.
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